Medpace Faces New Investor Class Action Over Book‑to‑Bill and Cancellations
The cases turn on whether Medpace hid rising cancellations in a key orders-to-revenue metric investors use to gauge future growth.
Overview
- Shareholder class actions have been filed against Medpace, with Levi & Korsinsky and Bleichmar Fonti & Auld announcing suits and seeking investors to lead the case.
- The complaints say executives misled investors about achieving a 1.15x book‑to‑bill ratio and downplayed volatile project cancellations that threaten future work.
- Book‑to‑bill compares new contract awards to revenue recognized from backlog, so a lower ratio or higher cancellations can signal weaker growth ahead.
- Medpace’s disclosure of a 1.04x book‑to‑bill for the fourth quarter of 2025 preceded a stock drop of about 16%, which the filings cite as the key loss event.
- Investors who bought shares between April 22, 2025 and February 9, 2026 are being recruited for lead‑plaintiff roles in early June, and one firm says it is also probing reports of further book‑to‑bill erosion and an executive’s planned exit.